Tgfbr1 Haploinsufficiency Inhibits the Development of Murine Mutant Kras-Induced Pancreatic Precancer

被引:23
作者
Adrian, Kevin
Strouch, Matthew J.
Zeng, Qinghua [3 ,4 ]
Barron, Morgan R.
Cheon, Eric C. [5 ]
Honasoge, Akilesh
Xu, Yanfei [2 ]
Phukan, Sharbani [2 ]
Sadim, Maureen [2 ]
Bentrem, David J.
Pasche, Boris [3 ,4 ]
Grippo, Paul J. [1 ]
机构
[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Dept Surg, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol,Canc Genet Program, Chicago, IL 60611 USA
[3] Univ Alabama, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA
[4] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[5] Univ Illinois, Dept Surg, Mt Sinai Hosp, Chicago, IL 60680 USA
关键词
DUCTAL ADENOCARCINOMA; COLORECTAL-CANCER; TUMOR SUPPRESSION; BETA RECEPTORS; EXPRESSION; SMAD4; PROGRESSION; ACTIVATION; PROGNOSIS; NEOPLASIA;
D O I
10.1158/0008-5472.CAN-09-1705
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To dissect the role of constitutively altered Tgfbr1 signaling in pancreatic cancer development, we crossed Elastase-Kras(G12D) (EL-Kras) mice with Tgfbr1 haploinsufficient mice to generate EL-Kras/Tgfbr1(+/-) mice. Mice were euthanized at 6 to 9 months to compare the incidence, frequency, and size of precancerous lesions in the pancreas. Only 50% of all EL-Kras/Tgfbr1(+/-) mice developed preinvasive lesions compared with 100% of EL-Kras (wild-type Tgfbr1) mice. The frequency of precancerous lesions was 4-fold lower in haploinsufficient than in control mice. Paradoxically, the precancerous lesions of EL-Kras/Tgfbr1(+/-) mice were considerably larger than those in EL-Kras mice. Yet, the mitotic index of precancerous cells and the observable levels of fibrosis, lipoatrophy, and lymphocytic infiltration were reduced in EL-Kras/Tgfbr1(+/-) mice. We conclude that Tgfbr1 signaling promotes the development of precancerous lesions in mice. These findings suggest that individuals with constitutively decreased TGFBR1 expression may have a decreased risk of pancreatic cancer. [Cancer Res 2009;69(24):9169-74]
引用
收藏
页码:9169 / 9174
页数:6
相关论文
共 24 条
  • [1] Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO
  • [2] 2-B
  • [3] Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
    Bardeesy, Nabeel
    Cheng, Kuang-hung
    Berger, Justin H.
    Chu, Gerald C.
    Pahler, Jessica
    Olson, Peter
    Hezel, Aram F.
    Horner, James
    Lauwers, Gregory Y.
    Hanahan, Douglas
    DePinho, Ronald A.
    [J]. GENES & DEVELOPMENT, 2006, 20 (22) : 3130 - 3146
  • [4] SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
    Blackford, Amanda
    Serrano, Oscar K.
    Wolfgang, Christopher L.
    Parmigiani, Giovanni
    Jones, Sian
    Zhang, Xiaosong
    Parsons, D. Williams
    Lin, Jimmy Cheng-Ho
    Leary, Rebecca J.
    Eshleman, James R.
    Goggins, Michael
    Jaffee, Elizabeth M.
    Iacobuzio-Donahue, Christine A.
    Maitra, Anirban
    Cameron, John L.
    Olino, Kelly
    Schulick, Richard
    Winter, Jordan
    Herman, Joseph M.
    Laheru, Daniel
    Klein, Alison P.
    Vogelstein, Bert
    Kinzler, Kenneth W.
    Velculescu, Victor E.
    Hruban, Ralph H.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (14) : 4674 - 4679
  • [5] TGF-β signaling in tumor suppression and cancer progression
    Derynck, R
    Akhurst, RJ
    Balmain, A
    [J]. NATURE GENETICS, 2001, 29 (02) : 117 - 129
  • [6] Transforming growth factors beta 1, beta 2, and beta 3 and their receptors are differentially regulated during normal and impaired wound healing
    Frank, S
    Madlener, M
    Werner, S
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (17) : 10188 - 10193
  • [7] ENHANCED EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA ISOFORMS IN PANCREATIC-CANCER CORRELATES WITH DECREASED SURVIVAL
    FRIESS, H
    YAMANAKA, Y
    BUCHLER, M
    EBERT, M
    BEGER, HG
    GOLD, LI
    KORC, M
    [J]. GASTROENTEROLOGY, 1993, 105 (06) : 1846 - 1856
  • [8] Goggins M, 1998, CANCER RES, V58, P5329
  • [9] Grippo P. J., 2004, Pancreas, V29, P335, DOI 10.1097/00006676-200411000-00047
  • [10] Grippo PJ, 2003, CANCER RES, V63, P2016